#HER2

@FAndreMD Well, 1) #pharma can convince some a pill is #superhero , 2) why are we settling for adjuvant #CDKi for all working or not?!!!, if we gave #trastuzumab to all #BC Pt’s, we wouldn’t have had #adjuvant success for #HER2 #BC, we need to know who truly benefits before adjuvant use

96% Overwhelmingly Positive Reviews! Grab a friend and get in on the co-op FPS action!

Part 3/5 breast cancer lectures on neo/adjuvant her-2 therapies by our breast specialist Dr. Theo, with case presentations #breastcancer #her2 #noonconference https://t.co/tnU6xfmy9j
2

Part 3/5 breast cancer lectures on neo/adjuvant her-2 therapies by our breast specialist Dr. Theo, with case presentations #breastcancer #her2 #noonconference https://t.co/tnU6xfmy9j

Breast cancer is the 2nd most common cancer worldwide. Understanding a patient’s biomarker and #HER2 status of cancer cells can help guide treatment options. #bcsm https://t.co/RRrG0BqsT3

#ESMO 2020 presentation by #Pieris - A Phase 1 Dose Escalation Study of PRS-343, a #HER2/4-1BB #Bispecific Molecule, in Patients with HER2-positive Malignancies https://t.co/jbC1UxVfxv. $PIRS #PRS343

#Verzenio® Significantly Reduced the Risk of #Cancer Recurrence by 25% for People with #HR+, #HER2- High Risk Early #BreastCancer $LLY https://t.co/tXU1InCYi5

#PierisPharmaceuticals Presents Updated Data from Phase 1 Monotherapy and #Atezolizumab Combination Studies of #41BB/#HER2 Bispecific #PRS343 at the #ESMO20 $PIRS https://t.co/uwZAuCbMhe

#Novartis #Piqray® data show survival benefit for patients with #HR+/#HER2- advanced #BreastCancer with a #PIK3CAmutation https://t.co/MLLlEJduST

Here the link to download the full paper of the #monarchE trial just presented at #ESMO20 on adjuvant #abemaciclib added to #EndocrineTherapy in high-risk #HormoneReceptor+ #HER2− early #BreastCancer patients @OncoAlert #bcsm @ASCO_pubs #JCO #JClinOncol https://t.co/VaB0moklcN

Friends at #ESMO20 An Honor to present our @OncoAlert 🚨Colleague @ErikaHamilton9 👩‍⚕️🇺🇸 Discussing: #monarchE presented at ESMO presidential by Dr.Johnston ✅adding #abemaciclib to adjuvant #ET improves the outcomes of #HR+/#HER2- high risk #BreastCancer @weoncologists https://t.co/T0sYJ2RyFO

Exciting results at @myESMO #PresidentialSession #ESMO20 with the #monarchE trial simultaneously published in @ASCO_pubs: adding #abemaciclib to adjuvant #EndocrineTherapy improves the outcomes of #HormoneReceptor+/#HER2- high risk #BreastCancer patients

#bcsm @OncoAlert #JCO https://t.co/HyRiTcEAp1
4

Exciting results at @myESMO #PresidentialSession #ESMO20 with the #monarchE trial simultaneously published in @ASCO_pubs: adding #abemaciclib to adjuvant #EndocrineTherapy improves the outcomes of #HormoneReceptor+/#HER2- high risk #BreastCancer patients #bcsm @OncoAlert #JCO https://t.co/HyRiTcEAp1

There isn't a standard TKI for #EXON20 #HER2 #NSCLC Poziotinib seems to have some activity, but toxicity is not acceptable with 87% having a dose interruption so happy to see ZENITH20 ongoing w/alternative dosing & BID schedule #LCSM #ESMO20 @OncoAlert @EGFRResisters https://t.co/14FQGSwPs9

There isn't a standard TKI for #EXON20 #HER2 #NSCLC Poziotinib seems to have some activity, but toxicity is not acceptable with 87% having a dose interruption so happy to see ZENITH20 ongoing w/alternative dosing & BID schedule #LCSM #ESMO20 @OncoAlert @EGFRResisters https://t.co/14FQGSwPs9

$PIRS Reveals findings from early-stage studies evaluating PRS-343 for the treatment of HER2-positive solid tumors #PierisPharma #PierisPharmaceuticals #Tumor #HER2 https://t.co/vzvUq0ygdG

#ESMO20 Overall, poziotinib has some activity in #HER2 mutant NSCLC. RR 27.8% with median DOR of 5.1 months. Delivery limited by toxicity though, with frequent interruptions/dose reductions. The trial continues but with alternative dosing and BID schedule which may help. #LCSM https://t.co/ifXul6DTFG

#ESMO20 Overall, poziotinib has some activity in #HER2 mutant NSCLC. RR 27.8% with median DOR of 5.1 months. Delivery limited by toxicity though, with frequent interruptions/dose reductions. The trial continues but with alternative dosing and BID schedule which may help. #LCSM https://t.co/ifXul6DTFG

#ESMO20 Poziotinib in #HER2 mutant NSCLC had a response rate of 27.8%. Duration of response 5.1 months, median time on treatment 3.7 months, median PFS 5.5 months. #LCSM @OncoAlert https://t.co/tdA9xdq2z5

#ESMO20 Poziotinib in #HER2 mutant NSCLC had a response rate of 27.8%. Duration of response 5.1 months, median time on treatment 3.7 months, median PFS 5.5 months. #LCSM @OncoAlert https://t.co/tdA9xdq2z5

#ESMO20 There are 7 cohorts to ZENITH20, 3 have completed accrual. This presentation focuses on cohort 2, #HER2 mutant NSCLC. Heavily pretreated population with most having received IO therapy and some with prior HER2 therapy as well. #LCSM @OncoAlert https://t.co/LLqzHgodAv
2

#ESMO20 There are 7 cohorts to ZENITH20, 3 have completed accrual. This presentation focuses on cohort 2, #HER2 mutant NSCLC. Heavily pretreated population with most having received IO therapy and some with prior HER2 therapy as well. #LCSM @OncoAlert https://t.co/LLqzHgodAv

#ESMO20 Update on poziotinib in #HER2 mutant #NSCLC by Mark Socinski from the ongoing phase II ZENITH20 study. #LCSM @OncoAlert @AdventHealth https://t.co/kJwUcSqEDH

#ESMO20 Update on poziotinib in #HER2 mutant #NSCLC by Mark Socinski from the ongoing phase II ZENITH20 study. #LCSM @OncoAlert @AdventHealth https://t.co/kJwUcSqEDH

@CCR_AACR #ESMO20 for sure one target where we have had an array of drugs now available as well as #immunotherapy combination explored is #HER2🧬.
🟢Tucatinib
🟢T-DXd (DS-8201)
🟢Trastuzumab➕PD1/PDL1⛔️
@CCR_AACR 📝 looking at NK cells🟠 to potentiate ADCC. 💡hypothesis generating. https://t.co/AACTbsqFRn
2

@CCR_AACR #ESMO20 for sure one target where we have had an array of drugs now available as well as #immunotherapy combination explored is #HER2🧬. 🟢Tucatinib 🟢T-DXd (DS-8201) 🟢Trastuzumab➕PD1/PDL1⛔️ @CCR_AACR 📝 looking at NK cells🟠 to potentiate ADCC. 💡hypothesis generating. https://t.co/AACTbsqFRn

Dear Friends at #ESMO20 A pleasure to introduce our @OncoAlert 🚨Colleague @prat_aleix who discusses: #PALLAS presented by @elmayermd #palbociclib added to adjuvant endocrine therapy in early HR+/ #HER2 - #BreastCancer does not improve iDFS and DRFS Best @weoncologists #BCSM https://t.co/CrL2r6s3Pl

#Palbociclib Muestra Ser Eficaz en Pacientes con #Cáncer de Mama Avanzado #HER2-Positivo . https://t.co/pQBUYU1yPc

Next Page